1. Home
  2. AADI vs RAND Comparison

AADI vs RAND Comparison

Compare AADI & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • RAND
  • Stock Information
  • Founded
  • AADI 2011
  • RAND 1969
  • Country
  • AADI United States
  • RAND United States
  • Employees
  • AADI N/A
  • RAND N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • RAND Finance: Consumer Services
  • Sector
  • AADI Health Care
  • RAND Finance
  • Exchange
  • AADI Nasdaq
  • RAND Nasdaq
  • Market Cap
  • AADI 33.6M
  • RAND 38.1M
  • IPO Year
  • AADI N/A
  • RAND N/A
  • Fundamental
  • Price
  • AADI $1.43
  • RAND $15.91
  • Analyst Decision
  • AADI Buy
  • RAND
  • Analyst Count
  • AADI 2
  • RAND 0
  • Target Price
  • AADI $5.00
  • RAND N/A
  • AVG Volume (30 Days)
  • AADI 325.1K
  • RAND 2.6K
  • Earning Date
  • AADI 08-07-2024
  • RAND 08-02-2024
  • Dividend Yield
  • AADI N/A
  • RAND 7.09%
  • EPS Growth
  • AADI N/A
  • RAND 232.84
  • EPS
  • AADI N/A
  • RAND 2.23
  • Revenue
  • AADI $23,840,000.00
  • RAND $7,553,884.00
  • Revenue This Year
  • AADI $4.21
  • RAND N/A
  • Revenue Next Year
  • AADI $8.61
  • RAND N/A
  • P/E Ratio
  • AADI N/A
  • RAND $7.34
  • Revenue Growth
  • AADI 26.97
  • RAND 16.36
  • 52 Week Low
  • AADI $1.28
  • RAND $12.50
  • 52 Week High
  • AADI $7.24
  • RAND $19.60
  • Technical
  • Relative Strength Index (RSI)
  • AADI 42.41
  • RAND 50.29
  • Support Level
  • AADI $1.46
  • RAND $16.88
  • Resistance Level
  • AADI $1.69
  • RAND $17.79
  • Average True Range (ATR)
  • AADI 0.11
  • RAND 0.61
  • MACD
  • AADI 0.02
  • RAND 0.13
  • Stochastic Oscillator
  • AADI 36.67
  • RAND 50.28

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, diversified management company. The firm's investment objectives is to maximize the total return to the shareholders with current income combined with capital appreciation. Some of its portfolios include lumious, and GiveGab among others.

Share on Social Networks: